BioNxt Solutions Inc. (CSE: BNXT)

Market Cap	29.48M
Revenue (ttm)	30.64K
Net Income (ttm)	-6.42M
Shares Out	113.40M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	98,500
Open	0.240
Previous Close	0.245
Day's Range	0.240 - 0.260
52-Week Range	0.170 - 0.750
Beta	0.66
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 25, 2024

About BioNxt Solutions

BioNxt Solutions Inc. engages in R&D and manufacturing of thin-film (sublingual) and skin patch (transdermal) drug delivery for neurological and autoimmune diseases, enhancing patient compliance and bioavailability. It offers diagnostic screening tests, and new active pharmaceutical production and evaluation, including precision transdermal and oral dissolvable drug formulations; oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company was f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: BNXT

Financial Performance

In 2023, BioNxt Solutions's revenue was 372,247, an increase of 25.15% compared to the previous year's 297,442. Losses were -7.72 million, -37.60% less than in 2022.